AOL

GSK's Once-Daily Inhalers For Smoker's Lung Has Potential Benefits: Independent Organization Report

The Institute for Clinical and Economic Review (ICER) released a report on Monday assessing the clinical effectiveness and value of GSK Plc's (NYSE:GSK) chronic obstructive pulmonary disease (COPD) ...
Seeking Alpha

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

DUBLIN, June 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") today announced that it has entered into a definitive agreement to sell its remaining royalty ...
Becker's Hospital Review

FDA approves Glaxo’s triple therapy inhaler for COPD

The FDA approved United Kingdom-based GlaxoSmithKline’s Trelegy Ellipta, a once-daily inhaler that contains three medicines for chronic obstructive pulmonary disease. The inhaler, developed with the ...
Nasdaq

TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises

Theravance Biopharma TBPH announced that it has entered into an agreement to sell its remaining royalty interest in net sales of Trelegy Ellipta to GSK plc GSK for $225 million in cash. Theravance ...
AOL

What Does a Trelegy Inhaler Cost with Medicare?

Medicare Part D prescription drug plans may cover Trelegy Ellipta inhalers. Out-of-pocket costs can vary by plan and insurer, but you may only have to pay a 25% ...